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Abstract
Background: Clinicians are confronted with an increasing number of patients with thyroid nodules. Reliable
preoperative diagnosis of thyroid nodules remains a challenge because of inconclusive cytological examination of
fine-needle aspiration biopsies. Although molecular analysis of thyroid tissue has shown promise as a diagnostic
tool in recent years, it has not been successfully applied in routine clinical use, particularly in Chinese patients.
Methods: Whole-transcriptome sequencing of 19 primary papillary thyroid cancer (PTC) samples and matched
adjacent normal thyroid tissue (NT) samples were performed. Bioinformatics analysis was carried out to identify
candidate diagnostic genes. Then, RT-qPCR was performed to evaluate these candidate genes, and four genes were
finally selected. Based on these four genes, diagnostic algorithm was developed (training set: 100 thyroid cancer
(TC) and 65 benign thyroid lesions (BTL)) and validated (independent set: 123 TC and 81 BTL) using the support
vector machine (SVM) approach.
Results: We discovered four genes, namely fibronectin 1 (FN1), gamma-aminobutyric acid type A receptor beta 2
subunit (GABRB2), neuronal guanine nucleotide exchange factor (NGEF) and high-mobility group AT-hook 2
(HMGA2). A SVM model with these four genes performed with 97.0 % sensitivity, 93.8 % specificity, 96.0 % positive
predictive value (PPV), and 95.3 % negative predictive value (NPV) in training set. For additional independent
validation, it also showed good performance (92.7 % sensitivity, 90.1 % specificity, 93.4 % PPV, and 89.0 % NPV).
Conclusions: Our diagnostic panel can accurately distinguish benign from malignant thyroid nodules using a
simple and affordable method, which may have daily clinical application in the near future.
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Background
Thyroid cancer (TC) is the most common endocrine malig-
nancy [1]. Recently, the number of thyroid carcinoma cases
annually had increased by 4 % globally [2] and became the
fastest growing type of cancer in many countries [1, 3].
China also suffers a large burden from thyroid cancer [4, 5].
China accounts for a large portion of thyroid cancer pa-
tients around the world. Papillary thyroid cancer (PTC) ac-
counts for 80–85 % of all types of thyroid carcinomas [6].
As a result of the increased frequency of medical exami-
nations, such as ultrasonic examination, clinicians are con-
fronted with an increasing number of patients with thyroid
nodules. However, the majority of these thyroid nodules
are benign, and only a few cases are malignant [7, 8].
Therefore, accurately diagnosing thyroid nodules preopera-
tively is important for patients with thyroid cancer to
receive timely treatment appropriately. Also, those with be-
nign thyroid nodules can avoid unnecessary treatments,
such as diagnostic surgery. Preoperative diagnosis of thy-
roid nodules can also help to reduce medical burden of pa-
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Cytological examination by ultrasound-guided fine-
needle aspiration biopsy (US-FNAB) is the most accur-
ate and gold-standard preoperative diagnostic method
currently [9, 10]. However, about 17 % (10–26 %) of
FNAB are reported as indeterminate, and 6 % (1–11 %)
were nondiagnostic; while 72 % median (range 62–85 %)
of undertaken FNAB were benign, and 5 % (1–8 %) were
malignant [11]. As a consequence, most of these patients
with indeterminate result undergo unnecessary diagnos-
tic surgery, making them suffer from lifelong replace-
ment therapy of thyroid hormones and corresponding
surgical complications [12].
In recent years, molecular analysis of thyroid tissue
has shown promise as a diagnostic tool [8, 13–15]. A
microarray-based test, combining the expression levels
of 167 genes (The Afirma) can diagnose thyroid nodules
with 92 % sensitivity and 52 % specificity [13]. Another
panel, named ThyroSeq v2 assay, which consists of more
than 50 gene mutations and gene fusions (more than
1,000 hotspots), makes accurate diagnosis with 90 % sen-
sitivity, 93 % specificity, 83 % positive predictive value
(PPV), and 96 % negative predictive value (NPV) by
using next-generation sequence [8]. Other studies also
performed with impressive PPV or NPV [14–17]. Never-
theless, studies aforementioned have their limitations.
Some studies contain large amounts of gene alterations,
such as The Afirma and ThyroSeq v2 assay, which are ex-
pensive and difficult to promote, particularly in less-
developed countries. Some studies failed to show both
optimal sensitivity and specificity in validation analysis.
Moreover, majority of these panels were based on patients
from Western countries. Since genetic background is dif-
ferent between Asians and Western populations, whether
these panels could be successfully applied to Chinese pa-
tients still remain unknown.
Therefore, in the present study, we performed whole-
transcriptome sequencing of 19 paired-PTC tissue samples
and bioinformatics analysis to investigate global mRNA ex-
pression. By using molecular approaches and statistical
models, we successfully established a diagnosis model
that combines only four genes: fibronectin 1 (FN1),
gamma-aminobutyric acid type A receptor beta 2 sub-
unit (GABRB2), neuronal guanine nucleotide exchange
factor (NGEF), and high-mobility group AT-hook 2
(HMGA2). This diagnosis model could discriminate
malignant from benign thyroid nodules with both high
sensitivity and specificity in Chinese patients.
Methods
Next generation sequencing and bioinformatics analysis
Total RNA was extracted from tissue samples using TRI-
ZOL Reagent (Invitrogen) according to the manufacturer’s
protocol. After the quality test, The cDNA libraries
were prepared using Ion Total RNA-Seq Kit v2.0 (Life
Technologies) according to the manufacturer’s instructions.
The cDNA libraries were then processed for sequencing
using Illumina Hiseq 2500 according to the commercially
available protocols. Before reads mapping, clean reads were
obtained from the raw reads by removing the adaptor
sequences, reads with > 5 % ambiguous bases, and low-
quality reads. The clean reads were then aligned to the
human genome (version: GRCH37) using the MapSplice
program (v2.1.6, University of Kentucky, Lexington, KY,
USA). We applied Ebseq algorithm to screen out the differ-
ently expressed genes using the following criteria: 1) fold
change (FC) > 2 for up or downregulation; 2) false discov-
ery rate (FDR) < 0.05 and 3) P-Value < 0.05.
Patients and tissue collection
Primary TC samples or benign thyroid lesions and their
matched adjacent normal thyroid tissue samples were
obtained at the time of initial surgery from the First Af-
filiated Hospital of Wenzhou Medical University. Inclu-
sion and exclusion criteria are as follows, inclusion
criteria: patients with surgical indication; tumor size lar-
ger than 5 mm; papillary thyroid cancer or follicular thy-
roid cancer or anaplastic thyroid cancer or medullary
thyroid cancer or benign thyroid lesions; with accurate
postoperative pathological diagnosis; with informed con-
sent from patients. Exclusion criteria: tumor size less
than or equal to 5 mm; with inconclusive postoperative
pathological diagnosis; with other malignant tumors; pa-
tients with surgical contraindications. Samples were snap-
frozen in liquid nitrogen immediately after surgical resec-
tion and subsequently stored at a −80 °C freezer. All the
training and validation samples set used in this study are
snap frozen tissues. Histopathological slides were reviewed
retrospectively for all cases to confirm the histological
diagnosis and to ensure abundant cancer content of the
tumor by two pathologists. Detailed information about
these patients are shown in Additional files 1 and 2. In-
formed consent for the scientific use of biological material
was obtained from each patient and the work was ap-
proved by the Ethics Committee of the First Affiliated
Hospital of Wenzhou Medical University.
RNA isolation and RT-qPCR
Total RNA was isolated using TRIZOL Reagent (Invitrogen)
and reverse transcription (TOYOBO, Japan) was performed
according to the manufacturer’s instructions. Quantitative
real-time PCR (RT-qPCR) analysis was performed in tripli-
cate on the ABI prism 7500 sequence detection system (Ap-
plied Biosystems, USA) using the THUNDERBIRD SYBR
qPCR Mix (TOYOBO, Japan) according to manufacturer’s
instructions. The GAPDH mRNA level was used for
normalization. Primer sequences were as follows: FN1: 5′-
TGGCCCCCACCTTCTTG -3′ (forward) and 5′- TGCGG
GAAAAATCCCTTCTA -3′ (reverse); GABRB2: 5′- ACT
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GCCGTGTCACATCCTCTAA -3′ (forward) and 5′- TGG
AACTGTCAACTTGCTTCAAA -3′ (reverse); NGEF: 5′-
GAGCTGGAAATGGTGGTGAAG -3′ (forward) and
5′- TTCCGTGCGGCTCATTTT -3′ (reverse); HMG
A2: 5′- GACCCAAAGGCAGCAAAAAC -3′(forward)




We evaluated several methodologies for building statistical
models that can predict benign versus malignant thyroid
nodules based on expression level of the four genes. Fi-
nally, the SVM (support vector machine) was used for
classification. With the modeling platform of MATLAB
2014a, we establish the SVM model for the classification
of benign and malignant thyroid nodules by using Libsvm
3.20. During the development of SVM model, using the
training data, we chose the C-SVC and RBF kernel func-
tions and used the grid search method to debug the
model. The grid c bound was −8 to 8, the grid c step was
0.5, the grid g bound was −8 to 8, and the grid g step was
0.5. The fold number of cross validation was 5.
Plabel ¼ sgn Σni ¼ 0 wi exp ‐gamma xi‐xð Þj j2þ bð Þð Þ
Statistical analysis
Data on normal distribution were expressed as mean ±
standard variation (SD) and were compared with t-test.
Categorical variables were expressed as percentage and
were compared with Chi-square test or Fisher’s exact test,
as appropriate. All P values were two sided, and a P value
of < 0.05 was considered statistically significant. Statistical
analysis was performed with SPSS software version 19.0
(SPSS, Chicago, IL, USA). GraphPad Prism 5 (GraphPad
Software, USA) was used for graphs.
Results
Filtrating differentially-expressed genes in TC by whole-
transcriptome sequence
We performed whole-transcriptome sequencing of 19
paired-PTC tissue samples to filtrate differentially-
expressed genes. We identified a total of 212 differentially-
expressed genes from the 19 paired-PTC tissue samples
(log2FC > 1.0, FDR < 0.05 and P-Value < 0.05) (Fig. 1), in-
cluding 99 overexpressed and 113 downregulated genes,
Fig. 1 Differentially expressed mRNAs in PTC tissue samples and adjacent normal tissue samples are analyzed using hierarchical clustering. Each
row represents a single mRNA and each column represents one tissue sample. Red indicates high relative expression and green indicates low
relative expression
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and then the 99 overexpressed genes were given focus. We
raised the FC cut-off value to a higher level (log2FC > 4.0)
to obtain more limited genes, which are significantly over-
expressed. Only 33 overexpressed genes were identified. To
obtain genes that are highly associated with thyroid tumor,
we screened out the intersection of these 33 overexpressed
genes and adenocarcinoma related genes, including only 12
genes (Fig. 2). Then, we investigated the expression of these
12 overexpressed genes in our 19 paired PTC samples with
sequencing data (19 PTC and 19 NT). As shown in Fig. 2,
all 12 genes showed significant differential expression be-
tween TC and NT, with FN1, GABRB2, NGEF and
HMGA2 showing the best diagnostic value. Finally, these
four genes with the most diagnostic value were filtrated.
The flowchart of our study design is presented in Fig. 3.
Training set: establishing the diagnostic panel
To establish diagnostic panel, mRNA expression levels
of the four genes were assessed in 165 samples (100 TC
and 65 BTL) using RT-qPCR. Result of each gene is
shown in Fig. 4a. Each of four genes demonstrated de-
cent ability to differentiate malignancy and benignity.
Using SVM statistical model, we successfully established
diagnostic panel that combines the four genes (FN1,
GABRB2, NGEF and HMGA2). Results revealed that the
panel was able to differentiate thyroid nodules excel-
lently. 95.8 % (158/165 samples correctly classified) of
the samples were correctly classified (Sensibility: 97.0 %,
Specificity: 93.8 %, PPV: 96.0 %, NPV: 95.3 %).
Validation set: validating the panel in external
independent samples
To validate panel performance, mRNA expression levels
of the four genes were measured by RT-qPCR in another
204 samples (123 TC and 81 BTL). Similar to previous
data, relative expression level of the four genes were sig-
nificantly upregulated (Fig. 4b). The panel also achieved
high accuracy in validation set, with 91.7 % accuracy
(187/204 samples correctly classified). Only nine malig-
nant thyroid tumors (4.4 %) and 8 benign thyroid lesions
(3.9 %) were misclassified among all the 204 samples.
Panel performance based on RT-qPCR was satisfactory,
with 91.7 % sensitivity, 92.7 % sensitivity, 90.1 % specifi-
city, 93.4 % PPV and 89.0 % NPV.
Discussion
Thyroid cancer, particularly PTC, has become the fastest
growing type of cancer in recent years [1, 3]. Owing to the
Fig. 2 Expression of the 12 overexpressed genes in our sequencing data (19 PTC and 19 NT). **P < 0.05; ***P < 0.001
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frequency of medical examinations, clinicians are now faced
with an even increasing number of patients with thyroid
nodules, most of which, however, are benign [7, 8]. Avoid-
ing unnecessary surgery, especially total thyroidectomies,
thereby reducing surgery-associated risks and subsequent
treatments, is still an intractable challenge for clinicians.
Thus, accurately distinguishing benign from malignant thy-
roid nodules preoperatively is important.
Considering this challenge, previous studies have devel-
oped several diagnostic panels through high-throughput
technologies, like next-generation sequence and micro-
array [8, 13–15, 18, 19]. A prospective study evaluated
diagnostic molecular test consisting of 167 genes in inde-
terminate nodules, which presented high sensitivity (92 %),
but low specificity (52 %) [13]. Some additional research
reports consistent results in using the classifier [20, 21],
while some reported only 17 % malignancy rate confirm-
ation in indeterminate nodules [22]. Moreover, the test is
not cost-effective outside of North America [20]. Another
panel, named ThyroSeq v2 assay, which consists of more
than 50 gene mutations and gene fusions (more than
1,000 hotspots), performed with 90 % sensitivity, 93 % spe-
cificity, 83 % PPV, and 96 % NPV by using next-generation
sequence [8]. Other studies also achieved encouraging ef-
fects [14–19]. However, these diagnostic panels are too
complex and costly to apply in clinical practice. Also, they
have not yet been proven to be effective in Asian popula-
tion. Many studies have shown that genetic background is
different between Asians and Western populations. For ex-
ample, a gene expression classifier (Afirma) showed dis-
tinctly different sensitivity and specificity in different
populations partly because of different genetic background
[13, 20, 22–25]. What is more, Xing M et al. reported
BRAF mutation occurred in about 45 % of PTC patients in
the USA [26] while the rate reported in Asian was much
higher, 63.7 % in the study from Jin L et al. [27] and 58 %
in the study from Lee JH [28]. However, the rate of TERT
promoter mutation was much higher in Western popula-
tions than Asian population (about 10 % vs 4.1 %) [27, 29].
Moreover, the incidence of thyroid cancer is also different
between Asians and Western populations [3, 4].
In the present study, we developed a panel that presents
excellent performance in discriminating benign from ma-
lignant thyroid nodules by combining only four genes
(FN1, GABRB2, NGEF and HMGA2). Its performance was
further validated by independent external samples. To fur-
ther confirm its performance in FNAB samples, we also
tested the panel in 20 FNAB samples with indeterminate
result, which correctly recognized 17 of 20 with 85 % pre-
diction accuracy. In spite of the limited sample size, the
panel also showed good discriminating ability in FNAB
samples.
FN1 encodes fibronectin involved in cell adhesion and
migration processes, including embryogenesis, wound
healing, blood coagulation, host defense and metastasis.
This gene was reported to be differentially expressed in
human cancers [30]. Some research showed that FN1
could help distinguish benign from malignant thyroid
tumors [31, 32], which is consistent with our findings.
GABRB2 encodes gamma-aminobutyric acid A recep-
tor, beta 2 subunit. This gene was found to be related to
mental diseases, like schizophrenia [33, 34]. A recent
study revealed that GABRB2 is highly upregulated in
thyroid cancer [35]. In our study, GABRB2 was one of
the most significant upregulated genes in 203 differential
expression genes.
NGEF has been found to be associated with myopia and
obesity-related diseases [36, 37]. However, it is not yet well
studied in human cancer. A study from Korea had demon-
strated that NGEF is a differentially-expressed gene in
PTC [38]. We also found that NGEF is upregulated and
can be used for diagnosis.
Fig. 3 Flowchart of the study design. Totally 212 differential expressed
genes were identitied by using whole-transcriptome sequencing of 19
paired PTC tissue samples. Only 33 genes were identitied when log2FC >
4 and we only focusd on those 33 over expressed genes. Then we got
the intersection of those 33 over expressed genes and adenocarcinoma
related genes, including 12 genes. we investigated the expression of
these 12 overexpressed genes in our 19 paired PTC samples with
sequencing data, 4 genes with the most diagnostic value were picked
out (FN1, GABRB2, NGEF and HMGA2). High accuracy of diagnosis was
both realized in training set and validation set
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HMGA2 encodes protein that belongs to non-histone
chromosomal high mobility group (HMG) protein family.
This protein contains structural DNA-binding domains
and may act as a transcriptional regulating factor. Many
studies have confirmed that HMGA2 is important in
tumorigenesis and tumor progression [39–43], including
thyroid cancer [35, 44]. Chiappetta et al. reported that the
mRNA expression of HMGA2 is associated with malignant
phenotype in human thyroid neoplasias [44]. HMGA2 was
also used as a diagnostic marker in previous studies
[14, 45]. In our study, HMGA2 was significantly up-
regulated in primary TC tissue, compared with benign
and normal thyroid nodules.
Although we had successfully established a diag-
nostic panel with excellent performance, the current
study has several limitations. First, based on frozen
tissue samples, our panel was only tested in a small
FNAB size, so it needs to be validated in FNAB sam-
ples with large-sample size. Second, our study was a
single-center study; multi-center prospective studies
are needed.
Conclusions
In summary, this study successfully established a diagnostic
panel by using a simple and affordable method, which uti-
lized only four genes with excellent performance in Chinese
patients. We believe this panel could form the basis for a
robust, practical, and affordable molecular diagnostic tool
for clinical use in the near future.
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